Navigation Links
Synthetic Biologics Reports Second Quarter 2014 Financial Results and Operational Highlights
Date:8/14/2014

174;, Rebif®, Gilenya®, Aubagio® and Tecfidera®, is currently enrolling patients at four sites in the United States.
  • Synthetic Biologics continues discussions to attract a strategic partner to accelerate development of this innovative therapy for relapsing-remitting MS in women.
  • Prevention of C. difficile (C. diff.) Infections – SYN-004 Oral Enzyme
    SYN-004, Synthetic Biologics' lead anti-infective product candidate, is believed to be the first and only therapy designed to neutralize intravenous (IV) antibiotics in the gut. It is intended to protect and maintain the balance of bacterial flora in the gastrointestinal tract, to potentially prevent the devastating effects of C. diff.  The U.S. Centers for Disease Control and Prevention (CDC) has classified C. diff as an "urgent public health threat", surpassing Methicillin-resistant Staphylococcus aureus (MRSA) as the number one hospital-acquired infection in the United States. C. diff is a multidrug-resistant bacterium that infects 1.1 million U.S. patients annually,[iii] and 30,000 patients die with a C. diff infection annually[iv].

    C. diff Operational Highlights and Upcoming Milestones:

  • Completion of final preclinical toxicology study and subsequent filing of an Investigational New Drug (IND) application in anticipation of human clinical development expected in the upcoming quarter.
  • Initiation of Phase Ia and Ib clinical trials expected in the fourth quarter of 2014, with preliminary topline data expected by year-end 2014.  A Phase II efficacy study is expected to begin in the first half of 2015.
  • Clinical drug manufacturing of SYN-004 in accordance with GMP guidelines is currently underway pursuant to execution of an agreement with Evonik.
  • C. diff Clinical Advisory Board (CAB) comprised of industry leaders Mark Wilcox, M.D., (Chairman), C
    '/>"/>

  • SOURCE Synthetic Biologics, Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related biology technology :

    1. Synthetic Biologics Academic Collaborator to Present Novel Monoclonal Antibody Combination for Treatment of Whooping Cough (Pertussis) at 54th ICAAC
    2. Synthetic Biologics to Report Second Quarter 2014 Financial Results
    3. Synthetic Biologics on Track to Initiate Clinical Program for SYN-004 to Protect Against C. difficile
    4. Global Synthetic Biology Market 2014-2018
    5. Synthetic Biologics to Present at the 7th Annual OneMedForum San Francisco 2014 Conference
    6. Green Dot Develops Compostable Synthetic Leather Made with its Terratek® Flex Bioplastic
    7. Synthetic Biologics Announces Exercise of Underwriters Over-Allotment Option
    8. Synthetic Biologics Announces Proposed Public Offering of Common Stock
    9. Global Geosynthetics Market 2012-2016
    10. Process holds promise for production of synthetic gasoline
    11. Startup to Strengthen Synthetic Biology and Regenerative Medicine Industries with Cutting Edge Cell Products
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/29/2015)... ... July 29, 2015 , ... ... supplier, announces the launch of their 2nd generation cell therapy POD® design. The ... CT, but it also represents a new POD® design. , “G-CON first ...
    (Date:7/29/2015)... 2015  AmnioChor Inc., an early stage biotech startup ... to announce that the Musculoskeletal Transplant Foundation of ... in their seed round of development of the proprietary ... AmnioChor,s technology allows cryopreservation of the ... cells living within those tissues. Amnion is a well-established ...
    (Date:7/29/2015)... 2015  Indivior PLC (LON: INDV) today announced that ... was accepted and received Priority Review by the U.S. ... opioid overdose. This naloxone nasal spray comes as a ... absorption into the nasal mucosa. 1 The device ... may be better equipped to help an opioid overdose ...
    (Date:7/29/2015)... QUEBEC CITY , July 29, 2015 /PRNewswire/ ... (the "Company") today announced it has selected an optimized ... important milestone in the development of a new ... The MAPK pathway represents a prime target for ... significant antitumor activities and survival benefits for B-Raf ...
    Breaking Biology Technology:G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
    ... , PHILADELPHIA, Sept. 16 BioNanomatrix, Inc., a ... and personalized medicine, today announced that Dr. Charles Lee and ... Dr. Lee is a pioneer in the field of ... Medical School and the Broad Institute. Dr. Barker, the ...
    ... , , , ... Pervasis Therapeutics, Inc. today announced that it completed the ... financing. The proceeds will be used primarily to support ... biologically active therapy designed to reestablish healthy vasculature following ...
    ... DENVER, Colorado and JERUSALEM, September 16 ... Venture announced today,that Children,s Hospital is enrolling patients for ... series of cord blood transplant sites,worldwide, five of which ... Spain, Italy, Hungary and Israel. The trial is researching ...
    Cached Biology Technology:BioNanomatrix Appoints Genomic Research Experts Charles Lee and David L. Barker as Advisers 2BioNanomatrix Appoints Genomic Research Experts Charles Lee and David L. Barker as Advisers 3BioNanomatrix Appoints Genomic Research Experts Charles Lee and David L. Barker as Advisers 4Pervasis Therapeutics Announces $17 Million in Financing and New Board Member 2Pervasis Therapeutics Announces $17 Million in Financing and New Board Member 3Pervasis Therapeutics Announces $17 Million in Financing and New Board Member 4Children's Hospital in Colorado Rounds off List of 24 Cord Blood Transplant Centers Worldwide Enrolling for ExCell Trial Studying StemEx(R) for Leukemia and Lymphoma 2Children's Hospital in Colorado Rounds off List of 24 Cord Blood Transplant Centers Worldwide Enrolling for ExCell Trial Studying StemEx(R) for Leukemia and Lymphoma 3Children's Hospital in Colorado Rounds off List of 24 Cord Blood Transplant Centers Worldwide Enrolling for ExCell Trial Studying StemEx(R) for Leukemia and Lymphoma 4
    (Date:7/31/2015)... Conn. , Jul. 31, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... that it has filed provisional patent 62/198989 for ... This invention highlights a method to advance crypto-currencies such ... by introducing a common, uniform way to manage all ...
    (Date:7/27/2015)... July 27, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced that Huawei has selected the ... for its stylish smartwatch. Huawei chose the state-of-the-art ... low power and highly responsive human interface qualities ... designers also required a classic round watch face ...
    (Date:7/23/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/rzzp3v/global_outlook_of ... "Global Outlook of the Biometrics Industry 2015 " ... The global biometrics market is likely to witness ... owing to the uptake of multiple technologies available. ... enhances the growth of biometrics in existing applications ...
    Breaking Biology News(10 mins):NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3
    ... at the Johns Hopkins School of Medicine have discovered ... protein, critical for the development of spinal cord neurons. ... describes a never-before known mechanism of protein control. ... of chemical reaction control neuronal differentiation," says Shanthini Sockanathan, ...
    ... September 17th, 2009 / b3c newswire / - ... based on a 96 well plate. The System ... EMBL (European Molecular Biology Laboratory). , PROcellcare ... (in vitro) under the microscope with biological nutrient ...
    ... cells in the body could help scientists better understand how ... have found that the protein invadolysin, which is essential for ... parts of cells used to store fat. The study ... reduced amounts of fat deposits. The findings, published in ...
    Cached Biology News:Antioxidant controls spinal cord development 2New Automatic cell feeding station PROcellcare for life cell imaging 2
    Rad 50 Immunogen: c-terminal mRad 50 (604 amino acids). Storage: 4 C...
    ... System is ideal for developing single and ... system contains the new, improved, and user ... user can design specific templates for commercial ... fully integrated graphing and data regression capabilities; ...
    ...
    ... GeneSwitch Cell Lines stably express the ... cell line is functionally tested for ... the expression control vector pGene/V5-His/lacZ and ... treatment with mifepristone (Figure 1). These ...
    Biology Products: